A novel formulation of the prostate cancer drug abiraterone acetate – currently marketed as Zytiga – will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials show the new formulation improves the drug’s effectiveness by 40 per cent.
Breakthrough discovery to transform prostate cancer treatment
A novel formulation of the prostate cancer drug abiraterone acetate – currently marketed as Zytiga – will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials show the new formulation improves the drug’s effectiveness by 40 per cent.